Pharmaceutical companies moving into the IO space have developed an obsession with PD-1 and PD-L1. The targets have spawned blockbuster drugs including Keytruda which are providing real hope for people with cancer. In fact, within a few short years PD-1 and PD-L1 drugs have become widely recognised as the therapeutic backbone around which combination therapies can be developed and trialled.
Stanford has now shone a spotlight into the world of immune suppression. What they have illuminated is profoundly important. Myc is the master regulator.
According to the Stanford research, Myc causes an increase in proteins that promote cell division - we knew that - and evasion of the immune system - that's new! So far, the researchers have implicated Myc with CD47 and PD-L1. This could be a game changer except Myc is undruggable.
Get Myc could become the new buzzword in immuno-oncology. The value of a promising pre-clinical candidate for Myc will surprise to the upside. For Phylogica, the timing of its iMYC data pack may turn out to be just right.
PYC Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)